Precision Neuroscience. Transformational Therapies.
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted neuroscience therapies for neuropsychiatric and neurodevelopmental diseases. Its pipeline includes ENX-102 (GABA-A PAM for generalized anxiety disorder) and ENX-104 (for major depressive disorder with anhedonia), both in Phase 2 trials. The company raised a $157M Series B in 2024 to advance its programs.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
Aug 2021
Jun 2020
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
